A new clinical trial offers a potential pathway to address the critical organ shortage that claims tens of thousands of lives each year in the United States alone. Researchers at NYU Langone are now transplanting genetically modified pig kidneys into living patients, building on earlier successes with brain-dead recipients [[1]]. this groundbreaking work in xenotransplantation-the transplantation of organs between species-could one day not only alleviate the transplant waitlist but, according to trial lead Dr. Robert Montgomery, potentially offer organs superior to those available from human donors [[3]].
A groundbreaking clinical trial is underway that could offer a solution to the critical shortage of organs available for transplant. Led by Dr. Robert Montgomery, director of the Transplant Institute at NYU Langone, the trial involves transplanting genetically modified pig kidneys into living patients.
The first transplant in the study has already been completed, and another is planned for January. This research represents a significant step forward in the field of xenotransplantation – the process of transplanting living cells, tissues or organs from one species to another – and offers hope to the thousands of people on organ transplant waiting lists.
Could Pig Organs Eventually Outperform Human Ones?
Dr. Montgomery believes that pig organs have the potential to surpass human organs in terms of suitability for transplant. “We can continuously modify them to improve them, while that cannot be done with a human organ,” he told The Guardian. Ongoing genetic modifications are aimed at minimizing the risk of immune rejection, a major hurdle in transplantation.
The pursuit of xenotransplantation has been decades in the making. Previously, the field was described as “on the verge of realization, but the road is very long.” However, recent advancements, particularly the development of genetically engineered pigs, have dramatically altered the landscape.
Dr. Montgomery previously led the first successful transplant of a genetically modified pig kidney into a human in 2021, though that recipient was brain-dead. That initial success demonstrated a lack of immediate rejection and paved the way for trials involving living patients.
Improving Compatibility Through Additional Transplants
Studies conducted by Dr. Montgomery’s team have also shown promising results with the co-transplantation of a thymus gland – found in pigs – alongside the kidney. This approach appears to enhance immune compatibility, potentially reducing or even eliminating the need for lifelong anti-rejection medications.
While this new clinical trial is the first of its kind, pig organs have been transplanted into several critically ill patients in the past. Some of those patients unfortunately died or required the organ to be removed, but there are currently living recipients who continue to function with pig kidneys.
Currently, kidneys and hearts are considered the most promising organs for xenotransplantation. Lung transplants are more complex, and the use of pig livers remains largely unexplored.
A Personal Connection Fuels the Research
Dr. Montgomery’s dedication to this field is also deeply personal. He himself received a human heart transplant in 2018 after battling a hereditary disease that claimed the lives of his father and brother. He was also instrumental in developing paired donation chains and expanding the use of organs from donors with hepatitis C after successful treatment.
“If I stay alive and healthy, I will definitely consider a pig heart next time,” Dr. Montgomery said, adding that he frequently thinks about his children, who carry the same genetic predisposition to heart disease, and hopes to provide them with better options in the future.
With thousands of deaths occurring each year due to the lack of available organs, this research offers a beacon of hope for millions of patients worldwide. The potential to expand the donor pool through xenotransplantation could dramatically improve access to life-saving transplants.
